Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Infections 1Carcinoma, Hepatocellular 1

Interventions

pegfilgrastim 26Filgrastim 24Cyclophosphamide 8Docetaxel 7Etoposide 6pegylated granulocyte colony-stimulating factor 5Cytarabine 5eflapegrastim 4Granulocyte Colony-Stimulating Factor 4Leucovorin 3Fluorouracil 3Doxorubicin 3Cyclosporine 3Cefepime 3Caspofungin 3Carboplatin 3liposomal amphotericin B 2Vincristine 2Vancomycin 2Topotecan 2Methylprednisolone 2Methotrexate 2Itraconazole 2Irinotecan 2Ifosfamide 2Idarubicin 2Fluconazole 2Daunorubicin 2Cisplatin 2Amikacin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neutropenia × Anidulafungin × Clear all
NCT00068471 2013-06-19

Anidulafungin in Treating Immunocompromised Children With Neutropenia

National Cancer Institute (NCI)

Phase 1/2 Completed

Infections, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡